Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | LIG1 | P18858 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13924205 | 0.93 | FLT3 (0.55) | FLT3ALDH1A1KDM4EKMT2AMEN1 | |
| SCHEMBL642762 | 0.90 | FLT3 (0.60) | FLT3ALDH1A1KDM4EKMT2AMEN1 | |
| SCHEMBL13384225 | 0.89 | FLT3 (0.62) | FLT3ALDH1A1KDM4EKMT2AMEN1 | |
| SCHEMBL3955768 | 0.87 | FLT3 (0.66) | FLT3ALDH1A1KDM4EKMT2AMEN1 | |
| SCHEMBL2902590 | 0.87 | FLT3 (0.66) | FLT3ALDH1A1KDM4EKMT2AMEN1 | |
| SCHEMBL2374331 | 0.85 | HSP90AA1 (0.50) | FLT3ALDH1A1KDM4EGAABLM | |
| SCHEMBL10848792 | 0.85 | FLT3 (0.64) | FLT3ALDH1A1KDM4EGAAPTPN1 | |
| SCHEMBL7272605 | 0.84 | GAA (0.59) | FLT3ALDH1A1KDM4EKMT2AMEN1 | |
| SCHEMBL2545851 | 0.84 | FFAR4 (0.55) | FLT3ALDH1A1KDM4EKMT2AMEN1 | |
| SCHEMBL9868423 | 0.84 | MEN1 (0.48) | FLT3ALDH1A1KDM4EKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1537078-B1 | INDOLES HAVING ANTI-DIABETIC ACTIVITY | MERCK SHARP & DOHME (US) | 2010-04-14 | — | — | EP | disclosed |
| EP-1537078-B1 | INDOLES HAVING ANTI-DIABETIC ACTIVITY | MERCK SHARP & DOHME (US) | 2010-04-14 | — | — | EP | disclosed |
| US-7625933-B2 | Indoles having anti-diabetic activity | MERCK & CO., INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-7625933-B2 | Indoles having anti-diabetic activity | MERCK & CO., INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-7625933-B2 | Indoles having anti-diabetic activity | MERCK & CO., INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-20080119531-A1 | PPAR gamma agonists or partial agonists; type II diabetes, including hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and obesity; compounds have a thiazolidinedione or an oxazolidinedione substituent | MERCK SHARP & DOHME CORP. | 2008-05-22 | — | — | US | disclosed |
| US-20080119531-A1 | PPAR gamma agonists or partial agonists; type II diabetes, including hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and obesity; compounds have a thiazolidinedione or an oxazolidinedione substituent | MERCK SHARP & DOHME CORP. | 2008-05-22 | — | — | US | disclosed |
| US-20080119531-A1 | PPAR gamma agonists or partial agonists; type II diabetes, including hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and obesity; compounds have a thiazolidinedione or an oxazolidinedione substituent | MERCK SHARP & DOHME CORP. | 2008-05-22 | — | — | US | disclosed |
| US-7345085-B2 | Indoles having anti-diabetic activity | MERCK & CO., INC. (US) | 2008-03-18 | — | — | US | disclosed |
| US-7345085-B2 | Indoles having anti-diabetic activity | MERCK & CO., INC. (US) | 2008-03-18 | — | — | US | disclosed |
| US-20070161689-A1 | Indoles having anti-diabetic activity | MERCK SHARP & DOHME LLC | 2007-07-12 | — | — | US | disclosed |
| EP-1765329-A2 | INDOLES HAVING ANTI-DIABETIC ACTIVITY | Merck & Co., Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| US-7186746-B2 | Indoles having anti-diabetic activity | MERCK & CO., INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186746-B2 | Indoles having anti-diabetic activity | MERCK & CO., INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186746-B2 | Indoles having anti-diabetic activity | MERCK & CO., INC. (US) | 2007-03-06 | — | — | US | disclosed |
| WO-2006014262-A2 | INDOLES HAVING ANTI-DIABETIC ACTIVITY | MERCK & CO., INC. (US) | 2006-02-09 | — | — | WO | disclosed |
| US-20050277685-A1 | Indoles having anti-diabetic activity | MERCK SHARP & DOHME LLC | 2005-12-15 | — | — | US | disclosed |
| EP-1537078-A1 | INDOLES HAVING ANTI-DIABETIC ACTIVITY | Merck & Co., Inc. (US) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004020408-A1 | INDOLES HAVING ANTI-DIABETIC ACTIVITY | MERCK & CO., INC. (US) | 2004-03-11 | — | — | WO | disclosed |
| WO-2004020409-A1 | INDOLES HAVING ANTI-DIABETIC ACTIVITY | MERCK & CO., INC. (US) | 2004-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277685-A1 | Indoles having anti-diabetic activity | GPR119, PPARA, PPARG | FLT3 1469/4885ALDH1A1 1472/4885KDM4E 2186/4885 |
| US-20080119531-A1 | PPAR gamma agonists or partial agonists; type II diabetes, including hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and obesity; compounds have a thiazolidinedione or an oxazolidinedione substituent | PPARD, PPARG, PPARA | FLT3 172/4885ALDH1A1 1823/4885KDM4E 2218/4885 |
| US-20070161689-A1 | Indoles having anti-diabetic activity | GPR119, PPARA, PPARG | FLT3 1469/4885ALDH1A1 1472/4885KDM4E 2186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.